Post by VectorY

We are pleased to share our latest peer reviewed publication in Trends in Biotechnology, the result of a strong collaboration between VectorY Therapeutics, Wageningen University & Research, and led by PhD student Linda de Jong. Plug-in hybrid baculovirus expression vector for high yield recombinant adeno-associated virus gene therapy vector production. Link: https://lnkd.in/eDsztZkG Key Highlights:  - Developed a stable baculovirus vector with an integrated AAV Replicase (Rep) gene leaving two independent and flexible insertion sites for AAV Capsid and recombinant AAV genome sequences - Enabled high-yield recombinant AAV production using a single baculovirus vector - Demonstrated baculovirus vector stability through next-generation sequencing   Together, these findings establish a flexible and scalable platform for AAV manufacturing in insect cells, with the potential to support more efficient vector production.    This work expands on an earlier publication (March 2026) from the VectorY-WUR collaboration: Productivity and genetic stability of a novel baculovirus vector for multigene expression from independent transgene loci (Molecular Therapy Methods & Clinical Development, March 2026): https://lnkd.in/enph37tC Congratulations to everyone involved in advancing the tools, technologies, and insights that drive scientific advancement.  #VectorY #ALS #ALSResearch #ALSCommunity #ClinicalTrials #NeurodegenerativeDisease #vectorizedantibodies #AntibodyTreatments #AntibodyTechnology #WageningenUniversity